Peginterferon beta-1a

Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.^[4][5]

The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.^[4][5]

Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.^[6][5]

In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.^[4]

In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.^[5]

• Plegridy at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e